5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
May 2018 in “KU ScholarWorks (The University of Kansas)” Targeting 5α-reductase type 1 may help manage Tourette-like symptoms.
October 2025 in “CRC Press eBooks” June 2026 in “The Journal of Steroid Biochemistry and Molecular Biology”
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
1 citations
,
March 2021 in “F1000Research” Plant-based compounds might be effective, low-side-effect treatments for prostate cancer by blocking a specific enzyme.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.
49 citations
,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
4 citations
,
August 2010 in “Acta Biologica Hungarica” New steroidal compounds moderately block an enzyme related to testosterone conversion, less effectively than finasteride.
October 2017 in “The Journal of Urology” 5α-Reductase inhibitors can negatively impact sexual function.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
January 2007 in “日本看護学会抄録集 成人看護1” Certain amino acids in 5AR1 and 5AR2 are crucial for binding and resistance to Finasteride.
June 2021 in “F1000Research” Plant-based compounds may offer safer prostate cancer treatment with fewer side effects.
April 2026 in “The Journal of Steroid Biochemistry and Molecular Biology”
13 citations
,
November 2012 in “PubMed” 5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
1 citations
,
March 2022 in “British Journal of Clinical Pharmacology” 5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
October 2016 in “Letters in Drug Design & Discovery” July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
5 citations
,
February 1997 in “Bioorganic & Medicinal Chemistry” New compounds were made that effectively block a specific enzyme related to androgen conditions.
These medications for BPH have known risks and may have new side effects.
December 2013 in “The Journal of Urology”
5α-reductase inhibitors help treat prostate enlargement and hair loss but may cause side effects, requiring careful use.
December 2012 in “Canadian Urological Association Journal” 5-alpha reductase inhibitors help treat prostate issues in aging men, but their role in cancer prevention is debated.
12 citations
,
April 1995 in “Journal of Medicinal Chemistry” The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
9 citations
,
April 2020 in “The Journal of Urology” 5α-Reductase inhibitors don't cause depression.